CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Imiquimod for the Treatment of Genital Warts: A Review of Clinical Effectiveness and Cost-Effectiveness

Last updated: September 25, 2017
Project Number: RC0930-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary with Critical Appraisal
Result type: Report


  1. What is the clinical effectiveness of imiquimod for the treatment of genital warts?
  2. What is the cost-effectiveness of imiquimod for the treatment of genital warts?

Key Message

Evidence from systematic reviews with low quality included studies suggests that overall for patients with anogenital warts (AGW) compared to placebo, treatment with imiquimod (IMQ) is associated with statistically significantly greater clearance but statistically significantly greater adverse effects. It appears that for patients with AGW, there were no statistically significant differences in clearance or adverse effects with IMQ compared with podophyllin, podophyllotoxin, cryotherapy, or Mycobacterium w vaccine. However, definitive conclusions were not possible due to the low quality of the studies, or the limited number of studies, or both.Due to the uncertainty in the clinical effect, the cost-effectiveness of IMQ in the management of AGW is unclear.